NMRA 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Our current pipeline and expected updates from these programs are detailed in the table below.

• CV = cardiovascular; GCase = Glucocerebrosidase; M4 = Muscarinic Acetylcholine Receptor M4; NLRP3 = Nucleotide-binding Domain, Leucine-rich–containing Family, Pyrin Domain–containing-3; V1aR = Vasopressin 1a Receptor

• We expense research and development costs as incurred. Amounts recorded for external goods or services incurred for research and development activities that have not yet been invoiced are included in accrued liabilities in our consolidated balance sheets and often

• represent estimates. We estimate accrued expenses and the related research and development expense based on the level of services performed but not yet invoiced pursuant to agreements established with our service providers, according to the progress of preclinical studies, clinical trials or related…

• Interest income consists of interest earned on our cash and cash equivalents.

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• ALS = Amyotrophic lateral sclerosis; CK1δ= Casein Kinase I Isoform delta; GCase = Glucocerebrosidase; KOR = kappa opioid receptor; M4 = Muscarinic Acetylcholine Receptor M4; NLRP3 = Nucleotide-binding Domain, Leucine-rich–containing Family, Pyrin Domain–containing-3; V1aR = Vasopressin 1a Receptor; …

• We expense research and development costs as incurred. Amounts recorded for external goods or services incurred for research and development activities that have not yet been invoiced are included in accrued liabilities in our consolidated balance sheets and often represent estimates. We estimate ac…

• Interest income consists of interest earned on our cash equivalents and marketable securities and interest expense related to our Loan Agreement.

• reduced navacaprant program costs of $3.6 million due to reduced manufacturing costs incurred,

• a decrease in other costs of $7.4 million primarily due to no activity under our research and collaboration agreements with Amgen in the current period, compared to $6.3 million in the prior period. The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 20…

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• We have devoted a significant portion of our financial resources and efforts to building our organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential product candidates, building our prec…

• Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other c…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• We have devoted a significant portion of our financial resources and efforts to building our organization, acquiring technologies and companies, executing clinical and preclinical studies, conducting research and development, identifying and developing potential

• product candidates, building our precision neuroscience approach, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We have not c…

• Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other c…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• * Intended to satisfy the affirmative defense of Rule 10b5-1(c)

• ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)

• (1) Trading arrangement was originally adopted August 30, 2024.